Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 147, Issue -, Pages 218-226Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.01.084
Keywords
Flavonids; Apoptosis; Cell cycle arrest; ERK; Ovarian cancer
Categories
Funding
- NIH from the National Center for Research Resources [P20RR016477]
- NIH from the National Institute of General Medical Sciences (NIGMS) [P20GM103434]
- NIGMS, a component of the National Institutes of Health (NIH) [P20GM104932]
- COBRE grant [GM102488/RR032138]
- ARIA S10 grant [RR020866]
- FORTESSA S10 grant [OD016165]
- INBRE grant [GM103434]
- National Natural Science Foundation of China [C200501]
- National Key Research and Development Program [2016YFD0400805]
Ask authors/readers for more resources
Ovarian cancer is one of the leading causes of death related to the female reproductive system in western countries. Adverse side effects and resistance to platinum based chemotherapy have become the major obstacles for ovarian cancer treatment. Natural products have gained great attention in cancer treatment in recent years. Chinese bayberry leaves flavonoids (BLF) containing rich content of myricitrin (myricetin 3-O-rhamnoside) and a part of quercetrin (quercetin 3-rhamnoside) inhibited the growth of an ovarian cancer cell line A2780/CP70. Such inhibitory effects might be due to the induction of apoptosis and G1 cell cycle arrest. BLF treatment increased the expression of cleaved caspase-3 and -7 and induced apoptosis via a Erk-dependent caspase-9 activation intrinsic apoptotic pathway by up-regulating the proapoptotic proteins (Bad and Bax) and down-regulating the anti-apoptotic proteins (Bcl-xL and Bcl-2), which were also in consistency with the results from Hoechst 33342 staining and flow cytometry analysis. Furthermore, by reducing the expression of cyclin D1 and CDK4 and p-Erk, BLF elevated the distribution of G1 phase in cell cycle and thus caused G1 cell cycle arrest. Overall, these results indicated that BLP5 could be a valuable resource of natural compound for ovarian cancer treatment. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available